LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

Home・Akcijų sąrašas・Beam Therapeutics Inc

Beam Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

29.65 0.51

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

28.48

Max

30.02

Pagrindiniai rodikliai
By Trading Economics
Pajamos	357M 244M
Pardavimai	104M 114M
Pelno marža	214.091
Darbuotojai	511
EBITDA	368M 261M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+60.84% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	122M 3B
Ankstesnė atidarymo kaina	29.14
Ankstesnė uždarymo kaina	29.65

Naujienos nuotaikos

By Acuity

23%

77%

76 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

16.225 / 20.17 Palaikymas ir pasipriešinimas

Beam Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-05 23:43; UTC

Svarbiausios naujienos

New Zealand's Unemployment Rate Falls in 1Q

2026-05-05 23:20; UTC

Karštos akcijos

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

2026-05-05 21:48; UTC

Uždarbis

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

2026-05-05 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

2026-05-06 00:00; UTC

Rinkos pokalbiai

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

2026-05-05 23:39; UTC

Rinkos pokalbiai

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

2026-05-05 22:26; UTC

Rinkos pokalbiai

AMD Data-Center Business Continues to Surge -- Market Talk

2026-05-05 22:20; UTC

Rinkos pokalbiai

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

2026-05-05 22:08; UTC

Uždarbis

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

2026-05-05 22:07; UTC

Uždarbis

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:48; UTC

Uždarbis

Pan American Silver 1Q Adj EPS $1.09 >PAAS

2026-05-05 21:48; UTC

Uždarbis

Pan American Silver 1Q Rev $1.2B >PAAS

2026-05-05 21:42; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:38; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:30; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:29; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:26; UTC

Uždarbis

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

2026-05-05 21:25; UTC

Uždarbis

Alcon Inc. 1Q EPS 39c >ALC.EB

2026-05-05 21:25; UTC

Uždarbis

Alcon Inc. 1Q Rev $2.71B >ALC.EB

2026-05-05 21:24; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:18; UTC

Uždarbis

Mistras Backs 2026 Rev $730M-$750M >MG

2026-05-05 21:17; UTC

Uždarbis

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

2026-05-05 21:15; UTC

Uždarbis

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

2026-05-05 21:12; UTC

Uždarbis

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

2026-05-05 21:11; UTC

Uždarbis

SSR Mining 1Q Rev $581.8M >SSRM

2026-05-05 21:10; UTC

Uždarbis

SSR Mining 1Q Adj EPS $1.15 >SSRM

2026-05-05 21:10; UTC

Uždarbis

SSR Mining 1Q EPS $1.16 >SSRM

2026-05-05 21:08; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:01; UTC

Uždarbis

Intact Financial 1Q EPS C$4.12 >IFC.T

2026-05-05 21:01; UTC

Karštos akcijos

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Akcijų palyginimas

Kainos pokytis

Beam Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

60.84% į viršų

12 mėnesių prognozė

Vidutinis 48.38 USD 60.84%

Aukščiausias 80 USD

Žemiausias 24.18 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Beam Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Beam Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

16.225 / 20.17Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

76 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.